Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07726914) titled 'Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sanofi

Condition: Chronic Graft Versus Host Disease

Intervention: Drug: Belumosudil

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: August 6, 2026

Target Sample Size: 58

To know more, visit https://clinicaltrials.gov/study/NCT07726914

Published by HT D...